Immunologist/Neuroscientist who moved to the Biotechnology sector, interested in Life Science developments. #Biotech #Pharma #Covid19 #SARS_CoV_2
UK
Joined January 2009
- Tweets55.5K
- Following6.7K
- Followers6.3K
- Likes51
Luke Scicluna retweeted
Highly potent, stable nanobodies stop SARS-CoV-2 medicalxpress.com/news/2021-…
Luke Scicluna retweeted
New tool predicts sudden death in inflammatory #heart disease @johnshopkins @ScienceAdvances medicalxpress.com/news/2021-…
Luke Scicluna retweeted
Lilly bets $70M upfront but squeezes in a major $2B in biobucks for Kumquat and its small-molecule immuno-oncology work dlvr.it/S4fXn5 #strategy #competitiveintelligence #marketing #biotech #competitivemarketing #healthcare #pharma #pharmaceutical
Luke Scicluna retweeted
Lab bone marrow model grown from patient #cells successfully tests how the individual will respond to #platelets-boosting treatments. Image and research by Christian A Di Buduo et al @ABalduiniLab @unipv in @eLife. Read more on bpod.mrc.ac.uk/archive/2021/… with @MRC_LMS and @esbriolat
Luke Scicluna retweeted
Released @EMDB_EMPIAR & published @FrontiersIn, the wonderful #FIBSEM data set of Gemmata obscuriglobus; #Planctomycetes #Bacteria that have unique #Cell architectures with heavily invaginated #Membranes by Seeger et al. from @uppsalauni.
1/2
Luke Scicluna retweeted
New large study of mRNA vaccine effectiveness for people with prior Covid
"Among those vaccinated with BNT162b2, protection against infection was further enhanced and infection incidence was further reduced by prior infection"
medrxiv.org/content/10.1101/…
Luke Scicluna retweeted
The #COVID19 virus continues to change and the Delta variant is more transmissible compared to the other virus strains. Listen to Dr @mvankerkhove share what is known so far about the delta variant and how we can keep ourselves safe ⬇️
Luke Scicluna retweeted
High-throughput mapping of a whole rhesus monkey brain at micrometer resolution go.nature.com/2TC64ER
Luke Scicluna retweeted
New @CellRepMed
The durable immune response to covid lasting at least 8 months, with memory B cells and polyfunctional T cells
cell.com/cell-reports-medici…
@fredhutch @EmoryVaccineCtr
Luke Scicluna retweeted
And since it seems that my #sciartportfolioweek is getting a little bit gender biased, here a shoutout to this super brilliant #sciart animator.
I love the addition of more than the straight up #spike protein of #SARSCoV2
This Post is from an account that no longer exists. Learn more
Luke Scicluna retweeted
So proud that our paper on contact networks and #SARSCoV2 in PNAS is now online. Summary coming up. pnas.org/content/118/31/e202…
Luke Scicluna retweeted
Cumulative #DeltaVariant prevalence mapped around the world from outbreak.info/situation-repo…
And countries with a cumulative prevalence >5%. Note: bars indicate confidence intervals.
#B16172 #SARSCoV2
Luke Scicluna retweeted
Let's see, the first genomic sequence of #SARSCoV2 was posted 2nd week January 2020...19 months ago.
And NOW we're talking about standardizing diagnostic & surveillance tests?
HEY @US_FDA -- you awake?
A head-to-head comparison of anti-spike protein assays to determine SARS-CoV-2 antibody levels shows that the assays are not interchangeable and highlights the need to further standardize SARS-CoV-2 antibody testing. @JournalSpectrum skyw.io/7VPwpy
Luke Scicluna retweeted
Agree with @MalloryFreeberg , cooperation in science will get us far 👩🔬👩💻 Check out how
@EGAarchive teamed up with amazing resources to enable important #COVID19 and #SARSCoV2 research over the past year 🙌
A year ago, the @EGAarchive released its first #COVID19 dataset. Since then, we have been working very hard to provide:
🌍controlled access to datasets deposited from 3 continents
🖥️tools for data discovery, e.g. viral beacon and covid 19 data portal
More🧬ega-archive.org/blog/providi…
Luke Scicluna retweeted
In the @NEJM Covid-19 Vaccine Resource Center, @PaulSaxMD provides concise and engaging answers to clinicians’ questions about Covid-19 vaccination and to the questions and concerns patients will raise. #SARSCoV2 #IDTwitter
Luke Scicluna retweeted
“The market for inhaled therapeutics is large and growing rapidly, with significant opportunities to address unmet needs.”
#SARSCoV2 #covid19 #treatments
theguardian.com/business/202…
Luke Scicluna retweeted
This is BIG! Low-Cost Biosensor for Minute-Scale Detection of #SARSCoV2
👉 Costs $1.50, takes 6.5 minutes, & demonstrates high accuracy; can facilitate high-frequency testing in resource-limited settings!
Link: pnas.org/content/118/30/e210…
@delafuenteupenn @michaelmina_lab #COVID19
